The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer
In this podcast episode, listen to Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, as they discuss clinical implications of the latest data from ASCO 2021 on using androgen receptor–directed therapy for the treatment and management of patients with nonmetastatic castration-resistant prostate cancer.
Decera Clinical Education Oncology Podcast · Alicia K Morgans MD MPH, Karim Fizazi MD PhD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–targeting agents in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Topics include:
- Updated safety and patient preference data from the ARAMIS and ODENZA trials
- Choice of apalutamide, darolutamide, and enzalutamide
- Counseling patients on adverse events
- Managing patients with asymptomatic nonmetastatic CRPC
Presenters:
Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France
Alicia K. Morgans, MD, MPH
Associate Professor
Division of Oncology
Department of Medicine
Northwestern University
Chicago, Illinois
Link to full program, including downloadable slides:
https://bit.ly/36IEnNE
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.